Cart
sales@molnova.com
Pomalidomide-PEG1-CO2H
CAS No. 2139348-60-8
Pomalidomide-PEG1-CO2H( Pomalidomide-PEG1-C2-COOH )
Catalog No. M28266 CAS No. 2139348-60-8
Pomalidomide-PEG1-CO2H is a synthetic E3 ligase ligand-linker conjugate containing a Pomalidomide-based cereblon ligand and a 2-unit PEG linker.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 37 | In Stock |
|
| 10MG | 61 | In Stock |
|
| 25MG | 116 | In Stock |
|
| 50MG | 160 | In Stock |
|
| 100MG | 237 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 584 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NamePomalidomide-PEG1-CO2H
-
NoteResearch use only, not for human use.
-
Brief DescriptionPomalidomide-PEG1-CO2H is a synthetic E3 ligase ligand-linker conjugate containing a Pomalidomide-based cereblon ligand and a 2-unit PEG linker.
-
DescriptionPomalidomide-PEG1-CO2H is a synthetic E3 ligase ligand-linker conjugate containing a Pomalidomide-based cereblon ligand and a 2-unit PEG linker.(In Vitro):PROTACs contain two distinct ligands, one for the E3 ubiquitin ligase and the other for the target protein, linked by a linker.
-
In Vitro——
-
In Vivo——
-
SynonymsPomalidomide-PEG1-C2-COOH
-
PathwayOthers
-
TargetOther Targets
-
RecptorHBV
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2139348-60-8
-
Formula Weight389.36
-
Molecular FormulaC18H19N3O7
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 125 mg/mL (321.04 mM)
-
SMILESO=C(O)CCOCCNC1=CC=CC=2C(=O)N(C(=O)C12)C3C(=O)NC(=O)CC3
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Campagna MR, et al. Sulfamoylbenzamide derivatives inhibit the assembly of hepatitis B virus nucleocapsids. J Virol. 2013 Jun;87(12):6931-42.
molnova catalog
related products
-
[Tyr0] - α - CGRP, [...
[Tyr0] - α - CGRP, [Tyr0] - α - CGRP, rat
-
Crenulatin
Crenulatin has dual- direction effects on apoptosis of cerebral microvascular endothelial cells, inhibitive effect in 25 mg/L and stimulative effect in 100 mg/L group, respectively; the mechanism is related to the alterations of Fas/Bcl-2 expression and caspase-3 activity.
-
Ruplizumab
Ruplizumab (BG 9588), a humanized monoclonal IgG1κ antibody targeting CD40L (TNF Receptor), holds promise for research in systemic lupus erythematosus disease .
